GlaxoSmithKline holds dividend, eyes IPO of HIV unit
October 22, 2014 at 07:23 AM EDT
LONDON, Oct 22 (Reuters) - GlaxoSmithKline kept its dividend unchanged for the third quarter, breaking a run of steadily rising payouts, as U.S. pricing pressure on its top-selling lung drug Advair eroded sales and profit.
